Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

ONPATTRO Concentrate for solution for infusion (2020)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Onpattro 2 mg/mL concentrate for solution for infusion.

Qualitative and quantitative composition

Each mL contains patisiran sodium equivalent to 2 mg patisiran. Each vial contains patisiran sodium equivalent to 10 mg patisiran formulated as lipid nanoparticles. Excipients with known effect: Each mL ...

Pharmaceutical form

Concentrate for solution for infusion (sterile concentrate). White to off-white, opalescent, homogeneous solution (pH: 6.3–7.5).

Therapeutic indications

Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Posology and method of administration

Therapy should be initiated under the supervision of a physician knowledgeable in the management of amyloidosis. Posology The recommended dose of Onpattro is 300 micrograms per kg body weight administered ...

Contraindications

Severe hypersensitivity (e.g., anaphylaxis) to the active substance or any of the excipients listed in section 6.1.

Special warnings and precautions for use

Infusion-related reactions IRRs have been observed in patients treated with Onpattro. In patients experiencing an IRR, the majority experienced the first IRR within the first 2 infusions (see section 4.8). ...

Interaction with other medicinal products and other forms of interaction

No formal clinical drug interaction studies have been performed. Onpattro is not expected to be affected by inhibitors or inducers of cytochrome P450 enzymes or to cause drug-drug interactions, except ...

Fertility, pregnancy and lactation

Women of childbearing potential Treatment with Onpattro reduces serum levels of vitamin A. Both too high or too low vitamin A levels may be associated with an increased risk of foetal malformation. Therefore, ...

Effects on ability to drive and use machines

On the basis of the pharmacodynamic and pharmacokinetic profiles, Onpattro is considered to have no or negligible influence on the ability to drive or use machines.

Undesirable effects

Summary of the safety profile The most frequently occurring adverse reactions reported in Onpattro-treated patients were peripheral oedema (29.7%) and infusion-related reactions (18.9%). The only adverse ...

Overdose

In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and given symptomatic treatment, as appropriate.

Pharmacodynamic properties

Pharmacotherapeutic group: Other nervous System Drugs ATC code: N07XX12 Mechanism of action Onpattro contains patisiran, a double-stranded small interfering ribonucleic acid (siRNA) that specifically targets ...

Pharmacokinetic properties

The pharmacokinetic properties of Onpattro were characterised by measuring the plasma concentrations of patisiran and the lipid components DLin-MC3-DMA and PEG<sub>2000</sub>-C-DMG. Absorption Greater ...

Preclinical safety data

General toxicology Liver and spleen were the primary target organs of toxicity in both rats and monkeys. Intravenous administration of Onpattro led to increases in serum liver markers (ALT, AST, ALP, and/or ...

List of excipients

DLin-MC3-DMA ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate) PEG2000-C-DMG (α-(3'propyl)ω-methoxy,polyoxyethylene) DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) ...

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Shelf life

Shelf life Unopened vials: 30 months. After dilution: Chemical and physical in-use stability has been demonstrated for 16 hours at room temperature (up to 30°C). From a microbiological point of view, it ...

Special precautions for storage

Store in a refrigerator (2°C to 8°C). Do not freeze. If refrigeration is not available, Onpattro can be stored at room temperature up to 25°C for up to 14 days. For storage conditions after dilution of ...

Nature and contents of container

5 mL concentrate in a Type I glass vial with a chlorobutyl stopper and an aluminium flip-off cap. Pack size of 1 vial.

Special precautions for disposal and other handling

This medicinal product is for single-use only. Onpattro must be diluted with sodium chloride 9 mg/mL (0.9%) solution prior to intravenous infusion. The diluted solution for infusion should be prepared ...

Marketing authorization holder

Alnylam Netherlands B.V., Strawinskylaan 3051, 1077 ZX, Amsterdam, Netherlands

Marketing authorization number(s)

EU/1/18/1320/001

Date of first authorization / renewal of the authorization

Date of first authorisation: 27 August 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: